GlobalResearch and clinical trials
Enzyme therapy in infant-onset LAL deficiency: 27 of 29 babies in the registry are alive
In the international LAL deficiency registry, 29 patients with the severe form starting in infancy were studied.
Lysosomal storage diseases
An inherited disease that causes fat and cholesterol to build up in the cells. It mainly affects the liver. It can begin in infancy or later.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
This page is translated from the Turkish original.
This disease is followed through the “Lysosomal storage diseases” group.
An enzyme called lysosomal acid lipase is missing in the cells. This enzyme breaks down fats and cholesterol. When it is missing, fats build up in the cells, mostly in the liver. The liver grows larger and can harden over time.
The disease has two forms. The severe form begins in infancy, in the first weeks, and is the rarest. The milder form begins in childhood or adulthood.
Blood tests may show high liver values and cholesterol. Enzyme activity is measured in the blood; a dried blood spot can also be used. The diagnosis is confirmed with a genetic test that looks at the LIPA gene.
There is an approved enzyme treatment specific to the disease. In the infant form, early diagnosis and treatment are very important. Babies are also given a special fat-restricted diet and vitamin supplements. A stem cell or liver transplant may be considered for some people. Cholesterol and the liver are checked regularly. The doctor who follows the disease decides which treatment is suitable.
The disease is passed on through recessive inheritance. The mother and father are usually healthy carriers. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. Diseases of this kind may be more common in marriages between relatives. Testing brothers and sisters is important for early treatment. Genetic counselling is recommended.
Source: MedlinePlus Genetics: Lysosomal acid lipase deficiency · GeneReviews: Lysosomal Acid Lipase Deficiency
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
For all rare diseases: Nadir Hastalıklar Federasyonu
Links checked on October 8, 2026.
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
GlobalResearch and clinical trials
In the international LAL deficiency registry, 29 patients with the severe form starting in infancy were studied.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
Questions you can ask your doctor
ClinicalTrials.gov lists 1 active interventional study for this disease. 1 is recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.
Selected records (studies with a site in Türkiye first):
Early stage: safety and dose are being tested · Phase 1 · investigational (experimental)RecruitingNCT04532047
See all studies on ClinicalTrials.gov · Joining clinical trials
InternationalResearch and clinical trials
Records of 19 sibling pairs with Hunter syndrome were compared.
USANew treatments and approvals
The FDA has approved rebisufligene etisparvovec for children with Sanfilippo syndrome type A (MPS IIIA).
ChinaResearch and clinical trials
In China, 6 children with infantile-onset Pompe disease were given a single dose of gene therapy.
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:275761
No separate ICD-11 code; WHO classifies this disease under: 5C56.0Y
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.